Jubilant Biosys Limited

Jubilant Epicore LLC

Other

Jubilant Episcribe LLC

Dhanalakshmi Sivanandhan

Sridharan Rajagopal

Chandrika Mulakala

Saravanan Vadivelu

Murugan Chinnapattu

Pavan Kumar Gondrala

Chandregowda Venkateshappa

Subramanyam Janardhan Tantry

Purushottam Dewang

Payal Kiran Parikh

Manjunatha M Ramaiah

Chandru Gajendran

Mohd Zainuddin

Sreekala Nair

Mahanandeesha S Hallur

Kannan Murugan

Sriram K Rajagopal

Rajagopal Bakthavatchalam

Raghava Reddy Kethiri

Swapan Kumar Samanta

Pravin Iyer

Muralidhar Pendyala

Jeyaraj D A

Durga Prasanna Kumar CH

Hariprakash

Sayantani Sarkar

Zainuddin Mohd

Subramaniam Kanagaraj

Nagendra Nagaraju

Indu N Swamy

Tamizharasan Natarajan

Manish Kumar Thakur

Shivani Garapaty

Raghunadha Reddy Burri

Sanjeev Giri

Vellarkad Narayana Viswanadhan

Durga Prasanna Kumar C H

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation. 

Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like. 

Heterocyclic compounds as PRMT5 inhibitors

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like. 

The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains. 

Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer

The present disclosure describes heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention, or suppression of diseases, an conditions mediated b one or more BET family of bromodomains.

Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors

Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer

The present disclosure describes heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases. 

Substituted pyrimidine compounds, compositions and medicinal applications thereof

Growing community of inventors

Bengaluru, India

Dhanalakshmi Sivanandhan